BioSpace News Archive

iTeos Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2022 and provided recent corporate highlights.

4D Molecular Therapeutics, Inc. reported first quarter 2022 financial results and provided corporate updates.

Sandoz announced the US launch of its generic pirfenidone, the first AB-rated equivalent to Genentech’s Esbriet®*, to treat patients with idiopathic pulmonary fibrosis.

NeuroOne Medical Technologies Corporation announces its operating results for the second quarter of fiscal year 2022 ended March 31, 2022.

Co-Diagnostics, Inc., a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced financial results for the first quarter ended March 31, 2022.

Regulus Therapeutics Inc. reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.

Poseida Therapeutics, Inc. announced updates and financial results for the first quarter ended March 31, 2022.

Trevi Therapeutics, Inc. announced financial results for the quarter ended March 31, 2022, as well as provided business updates.

Kezar Life Sciences, Inc. reported financial results for the first quarter ended March 31, 2022 and provided a business update.

Xeris Biopharma Holdings, Inc. announced it is presenting new data on the burden of illness in Cushing’s syndrome and the double-blind, placebo-controlled LOGICS study of Recorlev® in CS during the Pituitary Disorders/Neuroendocrinology ePoster sessions at the American Association of Clinical Endocrinology Annual Meeting, May 12-14, 2022.